Acta Scientific Orthopaedics (ISSN: 2581-8635)

Editorial Volume 4 Issue 7

Bone Metastasis Treatments, Major Therapeutic Frontiers

Da-Yong Lu* and Bin Xu

School of Life Sciences, Shanghai University, Shanghai, China

*Corresponding Author: Da-Yong Lu, School of Life Sciences, Shanghai University, Shanghai, China.

Received: April 26, 2021; Published: June 01, 2021


  Cancer is the secondary leading disease-induced human mortality worldwide. 60 - 90% cancer mortality is caused by neoplasm metastasis [1-4]. Currently, anticancer drugs are the foremost therapeutic selection because a lot of diversity of tumor origins and drug responses. Several pathways can improve these therapeutic responses and benefiting for bone metastasis treatment;

Future Direction

Finding key genetic or molecular factors that is involving bone metastasis [5].

Development of high-active anticancer or antimetastatic drugs [6-9].

Drug mechanisms and targeting study [10,11].

Herbal medicine may promote human physiological conditions and integrity [12-14].

Personalized medicine is a growing drug selection paradigm that may optimize drug treatment against cancer growth and metastasis [15-25].

Drug combination is an important pathway to promote clinical outcomes yet much efforts should be made to streamline clinical practice [26,27].

Mathematics and computational aids [28-31].


  1. Lambert AW., et al. “Emerging biological principles of metastasis”. Cell 168 (2017): 670-691.
  2. Ahmad AS., et al. “Trends in the lifetime risk of developing cancer in Great Britain; Comparison of risk for those born from 1930-1960”. British Journal of Cancer 112 (2015): 943-947.
  3. Mehlen P and Puisieux A. “Metastasis; a question of life or death”. Nature Reviews Cancer 6 (2006): 449-458.
  4. Weidenfeld K and Barkan D. “EMT and stemness in tumor dormacy and outgrowth: Are they intertwined processes?” Frontiers in Oncology 8 (2018): 381.
  5. Pantano F., et al. “Integrin alpha 5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions”. Oncogene 40 (2021): 1284-1299.
  6. Lu DY and Che JY. “Bone disease treatments, importance of technical supports”. Acta Scientific Orthopaedics4 (2021): 55-57.
  7. Lu DY., et al. “Cancer Metastasis treatments”. Current Drug Therapy1 (2013): 24-29.
  8. Lu DY., et al. “Anti-metastatic drug development, work out towards new direction”. Medicinal Chemistry7 (2018): 192-196.
  9. Lu DY and Lu TR. “Antimetastatic activities and mechanisms of bisdioxopiperazine compounds”. Anti-Cancer Agent Medicinal Chemistry7 (2010): 564-570.
  10. Zhu H., et al. “DJ-1 mediates the resistance of cancer cells to dihydroarteminisinin through cancer cells through reactive oxygen species removal”. Free Radical Biology and Medicine 71 (2014): 121-132.
  11. Lu DY., et al. “Development of antimetastatic drugs by targeting tumor sialic acids”. Scientia Pharmaceutica3 (2012): 497-508.
  12. Agarwal N., et al. “Natural herbs as anticancer drugs”. International Journal of PharmTech Research3 (2012): 1142-1153.
  13. Lu DY., et al. “Natural drug cancer treatment strategies from herbal medicine to chemical or biological drug”. Studies in Natural Products Chemistry 66 (2020): 91-115.
  14. Lu DY and Lu TR. “Herbal medicine in new era”. Hospice Palliative Medicine International Journal4 (2019): 125-130.
  15. Lu DY., et al. “Individualized cancer chemotherapy integrating drug sensitivity tests, pathological profile analysis and computational coordination-an effective strategy to improve clinical treatment”. Medical Hypotheses1 (2006): 45-51.
  16. Lu DY. “Personalized cancer chemotherapy, an effective way for enhancing outcomes in clinics”. Woodhead Publishing, Elsevier, UK (2014).
  17. Volm M and Efferth T. “Prediction of cancer drug resistance and implications for personalized medicine”. Frontiers in Oncology (2015): 282.
  18. Lu DY., et al. “Anticancer drug sensitivity testing, a historical review and future perspectives”. Current Drug Therapy1 (2015): 44-55.
  19. Lu DY and Lu TR. “Drug sensitivity testing, a unique drug selection strategy”. Advances in Biomarker Sciences and Technology 2 (2020): 59-66.
  20. Lu DY., et al. “Cancer bioinformatics for update anticancer drug developments and personalized therapeutics”. Reviews on Recent Clinical Trials2 (2017): 101-110.
  21. Lu DY., et al. “Pharmacogenetics of cancer therapy: breakthroughs from beyond?” Future Science OA4 (2015): 80.
  22. Montero J., et al. “Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy”. Cell 160 (2015): 977-989.
  23. Popova AA and Levkin PA. “Precision medicine in oncology: In vitro drug sensitivity and resistance test (DSRT) for selection of personalized anticancer therapy”. Advanced Therapeutics (2020): 1900100.
  24. Hyman DH., et al. “Implementing genome-driven oncology”. Cell 168 (2017): 584-599.
  25. Lu DY., et al. “Individualized cancer therapy, future approaches”. Current Pharmacogenomics and Personalized Medicine2 (2018): 156-163.
  26. Lu DY., et al. “Anticancer drug combination, how far we can go through?” Anti-Cancer Agents in Medicinal Chemistry 1 (2017): 21-28.
  27. Lu DY., et al. “Drug combination in clinical cancer treatment”. Reviews on Recent Clinical Trials3 (2017): 202-211.
  28. Franssen L., et al. “A mathematical framework for modeling the metastatic spread of cancer”. Bulletin of Mathematical Biology 81 (2019): 1965-2010.
  29. Gerlee P and Johanson M. “Inferring rates of metastatic dissemination using stochastic network models”. PLOS Computational Biology4 (2019): e1006868.
  30. Freedman DH. “Hunting for new drugs with AI”. Nature 576 (2019): s49-s53.
  31. Lu DY., et al. “Anatomic approaches for cancer metastatic study”. EC Clinical and Experimental Anatomy9 (2020): 32-34.


Citation: Da-Yong Lu and Bin Xu. “Bone Metastasis Treatments, Major Therapeutic Frontiers".Acta Scientific Orthopaedics 4.7 (2021): 01-02.


Copyright: © 2021 Da-Yong Lu and Bin Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate33%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is June 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US